| Symbol | AMPH |
|---|---|
| Name | AMPHASTAR PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 11570 6TH STREET, RANCHO CUCAMONGA, California, 91730, United States |
| Telephone | +1 909 980-9484 |
| Fax | — |
| — | |
| Website | https://www.amphastar.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The companys finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. Additional info from NASDAQ: |
New Form ARS - Amphastar Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-13 <b>AccNo:</b> 0001297184-26-000027 <b>Size:</b> 5 MB
Read moreNew Form DEFA14A - Amphastar Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-13 <b>AccNo:</b> 0001297184-26-000025 <b>Size:</b> 392 KB
Read moreNew Form DEF 14A - Amphastar Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-13 <b>AccNo:</b> 0001297184-26-000023 <b>Size:</b> 3 MB
Read moreAmphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
Read moreNew Form SCHEDULE 13G/A - Amphastar Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000687 <b>Size:</b> 7 KB
Read moreLiawatidewi Yakob 🔴 sold 1.0K shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $18.18 Transaction Date: Mar 15, 2026 | Filing ID: 000010
Read moreZhou Rong 🔴 sold 1.2K shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $18.18 Transaction Date: Mar 15, 2026 | Filing ID: 000010
Read morePETERS WILLIAM J 🔴 sold 2.0K shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $18.18 Transaction Date: Mar 15, 2026 | Filing ID: 000010
Read moreZhang Jack Y. 🔴 sold 12.7K shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $18.18 Transaction Date: Mar 15, 2026 | Filing ID: 000007
Read more(99% Neutral) AMPHASTAR PHARMACEUTICALS, INC. (AMPH) Announces Update on Collaboration with registeredCommon Stock
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05539872 | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity… | Phase2 | Pharmacokinetics | Completed | 2022-08-22 | 2023-01-30 | ClinicalTrials.gov |
| NCT04207840 | Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhala… | Phase4 | Pharmacokinetics | Completed | 2019-12-09 | 2019-12-23 | ClinicalTrials.gov |
| NCT02271334 | Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers | Phase2 | Asthma | Completed | 2014-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02210806 | Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evalua… | Phase2 | Asthma | Completed | 2014-07-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01737892 | Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults | Phase1 | Asthma | Terminated | 2012-11-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01737905 | Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asth… | Phase3 | Asthma | Completed | 2012-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01476904 | Safety Study in Adolescent and Adult Patients With Asthma | Phase3 | Asthma | Completed | 2011-11-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01460511 | Evaluation of Efficacy and Safety of E004 in Children With Asthma | Phase3 | Asthma | Completed | 2011-10-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01255709 | Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMAC… | Phase2 | Asthma | Completed | 2010-12-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01188577 | Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacok… | Phase1 | Asthma | Completed | 2010-08-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01174732 | Dose-Ranging Study of A006 DPI, in Adult Asthma Patients | Phase2 | Asthma | Completed | 2010-07-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01025648 | Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy… | Phase1 | Asthma | Terminated | 2009-12-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00634517 | 4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA i… | Phase3 | Asthma | Terminated | 2008-03-01 | 2008-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| NovoLog | DRUG | Phase PHASE2 | Pharmacokinetics | COMPLETED | NCT05539872 |
| I004 | DRUG | Phase PHASE2 | Pharmacokinetics | COMPLETED | NCT05539872 |
| Proventil® MDI | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT02271334 |
| A006 DPI | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT02271334 |
| Epinephrine HFA-MDI (E004) | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT01737905 |
| Arm C-Epinephrine Inhalation Aerosol CFC | DRUG | Phase PHASE1 | Asthma | TERMINATED | NCT01737892 |
| Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation | DRUG | Phase PHASE1 | Asthma | TERMINATED | NCT01737892 |
| Saline | DRUG | Phase PHASE2 | Allergic Skin Reaction | COMPLETED | NCT01689363 |
| Histamine | DRUG | Phase PHASE2 | Allergic Skin Reaction | COMPLETED | NCT01689363 |
| Hyaluronidase | DRUG | Phase PHASE2 | Allergic Skin Reaction | COMPLETED | NCT01689363 |
| Albuterol MDI 90 mcg/inh | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01581177 |
| Albuterol DPI 90 mcg/inh | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01581177 |
| Albuterol DPI 25 mcg/inh | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01581177 |
| Epinephrine inhalation | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT01476904 |
| Primatene Mist | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT01476904 |
| E004 (Epinephrine Inhalation Aerosol) HFA-MDI | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT01460511 |
| Epinephrine inhalation aerosol | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT01357642 |
| Arm C: Primatene Mist (epinephrine inhalation aerosol, USP) | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01255709 |
| Arm T2: Primatene Mist HFA | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01255709 |
| Arm T1: Primatene Mist HFA | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01255709 |
| Epinephrine Inhalation Aerosol | DRUG | Phase PHASE1 | Asthma | COMPLETED | NCT01188577 |
| Epinephrine Inhalation Aerosol, HFA | DRUG | Phase PHASE1 | Asthma | COMPLETED | NCT01188577 |
| epinephrine inhalation aerosol | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT01357642 |
| Proventil-HFA | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01189396 |
| Placebo DPI | OTHER | Phase PHASE2 | Asthma | COMPLETED | NCT02210806 |
| A006 | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01189396 |
| albuterol inhalation aerosol | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01174732 |
| Placebo | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT01476904 |
| albuterol inhalation powder | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01174732 |
| E004 (epinephrine inhalation aerosol), 160 mcg | DRUG | Phase PHASE1 | Asthma | TERMINATED | NCT01025648 |
| epinephrine inhalation aerosol, CFC propelled | DRUG | Phase PHASE1 | Asthma | TERMINATED | NCT01025648 |
| E004 (epinephrine inhalation aerosol), 220 mcg | DRUG | Phase PHASE1 | Asthma | TERMINATED | NCT01025648 |
| E004 (epinephrine inhalation aerosol), 125 mcg | DRUG | Phase PHASE1 | Asthma | TERMINATED | NCT01025648 |
| E004 Placebo | DRUG | Phase PHASE1 | Asthma | TERMINATED | NCT01025648 |
| E004 (epinephrine inhalation aerosol), 90 mcg/actuation | DRUG | Phase PHASE1 | Asthma | TERMINATED | NCT01025648 |
| HFA placebo | DRUG | Phase PHASE3 | Asthma | TERMINATED | NCT00635505 |
| albuterol HFA (Proventil HFA) | DRUG | Phase PHASE3 | Asthma | TERMINATED | NCT00635505 |
| albuterol HFA (Armstrong's) | DRUG | Phase PHASE3 | Asthma | TERMINATED | NCT00635505 |
| Placebo-HFA | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT01737905 |
| Albuterol Sulfate (Provenetil-HFA) | DRUG | Phase PHASE3 | Asthma | TERMINATED | NCT00634829 |
| albuterol (Armstrong Albuterol HFA) | DRUG | Phase PHASE3 | Asthma | TERMINATED | NCT00634829 |
| Albuterol Sulfate Inhalation Aerosol | DRUG | Phase PHASE3 | Asthma | TERMINATED | NCT00634517 |
| Armstrong Albuterol Sulfate Inhalation Aerosol | DRUG | Phase PHASE3 | Asthma | TERMINATED | NCT00634517 |